NASDAQ:SPRO
Spero Therapeutics Inc. Stock News
$1.59
+0.0200 (+1.27%)
At Close: May 17, 2024
Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023
08:05am, Monday, 06'th Nov 2023
CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commerciali
NEW YORK--(BUSINESS WIRE)-- #A--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Spero Therapeutics, Inc. (NASDAQ: SPRO) on b
Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer
08:05am, Wednesday, 01'st Nov 2023
Ms. Rajavelu brings over two decades of experience in the life sciences sector focused on strategic growth, financing, M&A, and investor relations. Ms. Rajavelu brings over two decades of experience i
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Tuesday, 31'st Oct 2023
CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commerciali
All You Need to Know About Spero Therapeutics, Inc. (SPRO) Rating Upgrade to Buy
01:32pm, Wednesday, 18'th Oct 2023
Spero Therapeutics, Inc. (SPRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
NEW YORK , Oct. 11, 2023 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim
Spero Therapeutics to Present at Cantor's Global Healthcare 2023 Investor Conference
04:05pm, Wednesday, 20'th Sep 2023
CAMBRIDGE, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and co
Spero Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
08:05am, Wednesday, 06'th Sep 2023
CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and co
Spero Therapeutics, Inc. (SPRO) Upgraded to Strong Buy: What Does It Mean for the Stock?
01:31pm, Tuesday, 29'th Aug 2023
Spero Therapeutics, Inc. (SPRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
New Strong Buy Stocks for August 29th
09:01am, Tuesday, 29'th Aug 2023
SPRO, FBIZ, KNSL, BMI and FDUS have been added to the Zacks Rank #1 (Strong Buy) List on August 29, 2023.
Down -11.72% in 4 Weeks, Here's Why Spero Therapeutics, Inc. (SPRO) Looks Ripe for a Turnaround
06:47pm, Tuesday, 22'nd Aug 2023
The heavy selling pressure might have exhausted for Spero Therapeutics, Inc. (SPRO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall S
Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Tops Revenue Estimates
07:46pm, Thursday, 10'th Aug 2023
Spero Therapeutics, Inc. (SPRO) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.87 per share a year ago.
Spero Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023
08:05am, Thursday, 03'rd Aug 2023
CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commerciali
Spero Therapeutics shares rise on FDA approval of pivotal complicated UTI trial
03:42pm, Monday, 31'st Jul 2023
Spero Therapeutics shares soared after the clinical-stage biopharmaceutical company announced that it has received special protocol approval from the United States Food and Drug Administration (FDA) f
Spero Therapeutics: The Multi-Asset Pipeline Could Outpace The Tebipenem HBr Deal With GSK
03:06pm, Wednesday, 05'th Jul 2023
Spero is eligible to receive up to $525 million in development and sales milestone payments as well as royalties on net product sales under the agreement with GSK. In addition, Spero has two other ass
